Q-omics provides the consensus-scored GLRA4 profile across patient tissues and cancer cell-line models. GLRA4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GLRA4 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, GLRA4 RNA expression shows 13,028 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where GLRA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLRA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLRA4 survival associations across molecular data types. GLRA4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLRA4 RNA expression–survival associations across cancer types. High GLRA4 expression shows unfavorable associations in KIRP, KICH, KIRC, MESO and ESCA, but favorable associations in READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KIRP as the clearest survival context for GLRA4 RNA expression.
This table summarizes GLRA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GLRA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLRA4 shows lower tumor expression in COAD, BRCA, BLCA, READ and UCEC and higher tumor expression in KIRC. The COAD box plot shows higher GLRA4 RNA expression in normal versus tumor tissue (log2 FC = −1.338, t-test p < 0.001).
This table shows molecular features associated with GLRA4 in patient tissues and cancer cell lines. In patient samples, GLRA4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GLRA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
